SG11202007018QA - Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy - Google Patents

Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy

Info

Publication number
SG11202007018QA
SG11202007018QA SG11202007018QA SG11202007018QA SG11202007018QA SG 11202007018Q A SG11202007018Q A SG 11202007018QA SG 11202007018Q A SG11202007018Q A SG 11202007018QA SG 11202007018Q A SG11202007018Q A SG 11202007018QA SG 11202007018Q A SG11202007018Q A SG 11202007018QA
Authority
SG
Singapore
Prior art keywords
ctla
antibodies
selecting
methods
cancer therapy
Prior art date
Application number
SG11202007018QA
Inventor
Yang Liu
Pan Zheng
Fei Tang
Mingyue Liu
Martin Devenport
Xuexiang Du
Yan Zhang
Original Assignee
Oncoimmune Inc
Childrens Research Institute Childrens National Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc, Childrens Research Institute Childrens National Medical Center filed Critical Oncoimmune Inc
Publication of SG11202007018QA publication Critical patent/SG11202007018QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
SG11202007018QA 2018-02-02 2019-01-29 Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy SG11202007018QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625662P 2018-02-02 2018-02-02
US201862647123P 2018-03-23 2018-03-23
PCT/US2019/015664 WO2019152413A1 (en) 2018-02-02 2019-01-29 Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy

Publications (1)

Publication Number Publication Date
SG11202007018QA true SG11202007018QA (en) 2020-08-28

Family

ID=67479455

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007018QA SG11202007018QA (en) 2018-02-02 2019-01-29 Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy

Country Status (11)

Country Link
US (1) US20210047410A1 (en)
EP (1) EP3746122A4 (en)
JP (2) JP2021511812A (en)
KR (1) KR20200142498A (en)
CN (1) CN112135632A (en)
AU (1) AU2019216228A1 (en)
CA (1) CA3089704A1 (en)
IL (1) IL276446A (en)
SG (1) SG11202007018QA (en)
TW (1) TW201945029A (en)
WO (1) WO2019152413A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542332B2 (en) * 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109715210B (en) * 2016-09-19 2023-05-30 昂科医药 CD80 and CD86 binding protein compositions and uses thereof
US11643463B2 (en) 2017-05-19 2023-05-09 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
EP4082572A4 (en) * 2019-12-25 2024-03-06 Bio Thera Solutions Ltd Anti-ctla-4 monoclonal antibody, preparation method therefor, and application thereof
CN116390949A (en) * 2020-11-06 2023-07-04 百时美施贵宝公司 Administration and administration of nonfucosylated anti-CTLA-4 antibodies as monotherapy
KR20240024255A (en) * 2021-06-25 2024-02-23 추가이 세이야쿠 가부시키가이샤 Use of anti-CTLA-4 antibodies
WO2023001987A2 (en) 2021-07-22 2023-01-26 University Of Dundee Therapeutic muteins
CN115044590B (en) * 2022-06-30 2023-08-15 昆明理工大学 Application of p53 gene mutant and protein expressed by same in preparation of medicines for diagnosing and treating hypertrophic cardiomyopathy
CN116183472B (en) * 2023-04-25 2023-08-18 上海益诺思生物技术股份有限公司 Verification method for detecting non-human primate cytokines by CBA method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532461T3 (en) * 2007-12-26 2015-03-27 Xencor, Inc. FC variants with altered FCRN binding
TWI667257B (en) * 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
GB201104950D0 (en) * 2011-03-24 2011-05-11 Univ Birmingham Immune assay
EP3508215A3 (en) * 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
EP3057990B1 (en) * 2013-10-18 2019-09-04 Regeneron Pharmaceuticals, Inc. Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
KR20240056629A (en) * 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 Modulation of stimulatory and non-stimulatory myeloid cells
CN108430499B (en) * 2015-12-15 2022-07-19 肿瘤免疫股份有限公司 Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
WO2017165778A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments

Also Published As

Publication number Publication date
KR20200142498A (en) 2020-12-22
IL276446A (en) 2020-09-30
EP3746122A1 (en) 2020-12-09
JP2021511812A (en) 2021-05-13
JP2023066423A (en) 2023-05-15
US20210047410A1 (en) 2021-02-18
TW201945029A (en) 2019-12-01
WO2019152413A1 (en) 2019-08-08
CN112135632A (en) 2020-12-25
AU2019216228A1 (en) 2020-08-13
EP3746122A4 (en) 2021-11-24
CA3089704A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
IL276446A (en) Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
IL267804A (en) Methods of treating cancer with anti-pd-1 antibodies
HK1252272A1 (en) Methods of treating cancer using anti-ox40 antibodies
IL267803A (en) Methods of treating cancer with anti-tim-3 antibodies
HK1251474A1 (en) Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
ZA202004735B (en) Anti-pd-1 antibodies and methods of treatment
IL262562A (en) Combination of anti-pd-1 antibodies and radiation to treat cancer
HK1245134A1 (en) Treatment of cancer with anti-lap monoclonal antibodies
IL266990A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
IL276303A (en) Methods for treating cancer with anti-pd-1 antibodies
IL279251A (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
IL289663A (en) Claudin18 antibodies and methods of treating cancer
IL268479A (en) Anti-pd-1 antibodies for treatment of lung cancer
IL273196A (en) Claudin6 antibodies and methods of treating cancer
IL281441A (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
IL275940A (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
IL277981A (en) Methods of treating cancer
IL287687A (en) Methods of treating cancer with an anti-pd-l1 antibody
SG11202108140SA (en) Anti-bag2 antibody and methods of treating cancer
GB201903012D0 (en) Antibodies for treatment of cancer and other diseases